On the risk of delisting of ordinary shares of Adverum Biotechnologies, Inc. (ADVM)

The International Trading System Limited (hereinafter — ITS) informs on the information concerning delisting risk of ordinary shares of Adverum Biotechnologies, Inc. (ISIN US00773U2078, Shares) from The NASDAQ Stock Market LLC (NASDAQ).

Information on delisting risk of ordinary shares by NASDAQ

On April 15, 2025, Adverum Biotechnologies, Inc. (the Company) submitted Annual report on Form 10-K to The United States Securities and Exchange Commission. According to the report, the Company has incurred losses since inception, substantial accumulated deficit, significant negative cash flows from operations, and the expectation that existing cash, cash equivalents, and short-term investments will not be sufficient to fund operations for at least 12 months from the date of the financial statement issuance. These conditions led the Company’s management to raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS

If NASDAQ suspends trading in the Company’s ordinary shares, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. If the Company’s ordinary shares are delisted from NASDAQ, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognised Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.